Treatment of acute HCV infection (Q37855530)

24 August 2017

1 reference

title

Treatment of acute HCV infection (English)

1 reference

24 August 2017

Gregory J Dore

1 reference

24 August 2017

Jason Grebely

1 reference

24 August 2017

Gail V Matthews

1 reference

24 August 2017

language of work or name

English

0 references

publication date

22 March 2011

1 reference

Nature Reviews Gastroenterology & Hepatology

24 August 2017

published in

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

265-274

1 reference

Global epidemiology of hepatitis C virus infection

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Surveillance for newly acquired hepatitis C in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Enhanced surveillance of newly acquired hepatitis C virus infection in Canada, 1998 to 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Epidemiology of hepatitis C virus infection in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

High hepatitis C incidence in new injecting drug users: a policy failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence Rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

High hepatitis C virus prevalence and incidence among Canadian intravenous drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Availability of body art facilities and body art piercing do not predict hepatitis C acquisition among injection drug users in Montreal, Canada: Results from a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

A cluster of acute hepatitis C virus infection among men who have sex with men--results from contact tracing and public health implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006: is this an outbreak?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Prospective evaluation of community-acquired acute-phase hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Hepatitis C: the clinical spectrum of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Improving the Diagnosis of Acute Hepatitis C Virus Infection with Expanded Viral Load Criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

New insights into the immunopathogenesis of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Immunological determinants of the outcomes from primary hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Acute hepatitis C virus infection: A chronic problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Adaptive immune responses in acute and chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Host genetic determinants of spontaneous hepatitis C clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Treatment of acute hepatitis C with interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Duration of peginterferon therapy in acute hepatitis C: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

A short course of pegylated interferon-alpha in acute HCV hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Twelve-week treatment of acute hepatitis C virus with pegylated interferon- alpha -2b in injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Barriers associated with the treatment of hepatitis C virus infection among illicit drug users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Hepatitis C treatment in pharmacotherapy services: increasing treatment uptake needs a critical view.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Current approaches to HCV infection in current and former injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Hepatitis C treatment for injection drug users: a review of the available evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Injection drug users: the overlooked core of the hepatitis C epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Follow-up studies of treatment for hepatitis C virus infection among injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCV/HIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2a/ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Ribavirin improves early responses to peginterferon through improved interferon signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Rate of Sustained Virologic Response in Relation to Baseline Hepatitis C Virus (HCV) RNA Level and Rapid Virologic Clearance in Persons with Acute HCV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Clinical presentation and course of acute hepatitis C infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Prevention and treatment of hepatitis C in injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Surveillance and epidemiology of hepatitis B and C in Europe - a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Prevention of hepatitis C in Italy: lessons from surveillance of type-specific acute viral hepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Peginterferon Alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic Response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Treatment duration in acute hepatitis C: the issue is not solved yet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.32

Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals.

31 March 2020

1 reference

12 December 2020

Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection

1 reference

12 December 2020

Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference.

1 reference

12 December 2020

Acute hepatitis C virus infection in incarcerated injection drug users

1 reference

12 December 2020

Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004

1 reference

12 December 2020

Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy

1 reference

12 December 2020

Prevention and treatment of hepatitis C in injection drug users

1 reference

12 December 2020

Surveillance for acute viral hepatitis - United States, 2007.

1 reference

12 December 2020

Current status of hepatitis C in Canada.

1 reference

12 December 2020

Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C.

1 reference

12 December 2020

Risk factors for hepatitis C virus infection among street youths

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRGASTRO.2011.32

1 reference

24 August 2017

1 reference